ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

VXRT Vaxart Inc

0,90
0,0353 (4,08%)
Após o horário de negociação
Última atualização: 17:05:08
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Vaxart Inc VXRT NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,0353 4,08% 0,90 17:05:08
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
0,88 0,8609 0,9499 0,9421 0,8647
mais cotações »

Notícias Recentes

Data Hora Fonte Título
13/05/202417:01GLOBEVaxart Provides Business Update and Reports First Quarter..
13/05/202408:10IHMARKETNEWSU.S. Futures Climb Amid High Expectations for Inflation..
07/05/202409:00GLOBEVaxart to Host First Quarter 2024 Business Update and..
30/04/202409:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/03/202409:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/03/202409:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
14/03/202417:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/03/202408:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07/03/202410:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06/03/202410:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
05/02/202410:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
19/01/202410:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
16/01/202411:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16/01/202411:22GLOBEVaxart, Inc. Announces Management Change
21/12/202310:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
02/11/202317:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202309:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202309:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
11/10/202309:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/09/202309:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
06/09/202317:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
03/08/202317:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
27/07/202309:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
06/07/202309:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
26/06/202317:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
21/06/202317:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
07/06/202310:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
06/06/202317:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
06/06/202309:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..
31/05/202309:00GLOBEVaxart Launches New Investor Communication Program, First..

Seu Histórico Recente